![](https://newshub-website-data.s3.ap-southeast-2.amazonaws.com/2024/02/13091407/Vitura-Logo.png)
APPOINTMENT OF ROBERT IERVASI AS INDEPENDENT CHAIR OF THE BOARD
Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to announce that Mr. Robert Iervasi has been appointed as Independent Chair and a Non-Executive Director of the Board, replacing Dr. Marcia Walker who has held the position of Interim Chair since September 2023. Dr. Walker will remain on the Board as an independent, Non-Executive Director.
The Board would like to thank Dr. Walker for her valuable contribution to the Company and her service as Interim Chair and looks forward to her continued leadership as an independent, Non-Executive Director.
Mr. Iervasi is a Chair, Board Director, former Group CEO, CFO and General Counsel. Most recently he was the Group CEO of Asahi Beverages, which owns Carlton and United Breweries (CUB). In this role, he was instrumental in the acquisition of CUB by Asahi in 2019 in a deal valued at $16 billion.
Currently, Mr. Iervasi serves as Chair at Luv-a-Duck and Charters Paper, and is a Non-Executive Director at SPC Global.
With a background in both corporate governance and consumer products, Mr. Iervasi is focussed on driving profitability and growth, utilising decades of experience as a CFO, General Counsel and CEO through the various executive and Board roles he has held, including Asahi Beverages, HS Fresh Foods Group, Allpress Expresso and Circular Plastics Australia. In these roles, he has leveraged a proven ability to identify opportunities, mitigate enterprise-wide risks and implement revenue and cost synergies.
Mr. Iervasi pays special attention to employee engagement which he believes is integral to the success of an integrated business and is, now more than ever, core business for boards. He has achieved this in previous roles whilst delivering above-market top-line and profit growth.
Reflecting on his significant commercial experience and proven FMCG experience, Mr. Iervasi is well placed to lead the Board of Vitura to enhance its operational performance, guide future acquisitions and integrations and to optimise its operating model to generate sustainable financial growth.
Mr. Iervasi holds a Bachelor of Commerce (Honours) majoring in Accounting and Finance, and a Bachelor of Laws (Honours) degree and has completed the Senior Executive Program at London Business School.
“Robert brings a wealth of experience to Vitura having recently concluded a distinguished executive career at a global level with Asahi Beverages as Group CEO, which delivered exceptional operational, and financial growth and the $16 billion acquisition of CUB. The Vitura team looks forward to building on our foundational growth under Robert’s Chairmanship,” said Rodney Cocks, Chief Executive Officer of Vitura.
“Joining Vitura at this time represents an exciting opportunity. The growth already achieved by Vitura, coupled with Vitura’s relentless ambition to enhance the healthcare experience, means that we are well placed to continue to grow and excite our consumers. I am looking forward to bringing my experience in consumer products and FMCG to Vitura as we work towards redefining healthcare in our markets,” said Mr. Iervasi.
Mr. Iervasi’s remuneration as Chair of Vitura is $120,000 per annum and he will join the Company’s Audit and Risk and Nomination and Remuneration Committees.
About us:
Vitura Health Limited is diversified digital health business listed on the ASX (ASX:VIT) and, via its wholly owned subsidiaries
Our subsidiaries, including CanView, Doctors on Demand, Cortexa, CDA Clinics, Cannadoc, BHC and Adaya, are actively contributing to the evolution of the Australian medical sector. This purpose-lead portfolio of companies aims to provide a seamless approach to patient treatment pathways, streamlined medication access for pharmacies, as well as unparalleled prescribing tools and education for clinicians.
Contact details:
Tim Fogarty, The Civic Partnership
+61 400 179 075